Search

for
Search:

Research

5 / 1000+ results

research Cutaneous toxicities of new treatments for melanoma

25 citations , May 2018 in “Clinical & Translational Oncology”

This review summarizes common skin-related side effects of BRAF inhibitors and immunotherapy in advanced melanoma treatment, reporting no new clinical findings, and emphasizes consensus management to improve patient outcomes.

research Effect of Sun exposure-induced ferroptosis mechanisms on pathology and potential biological processes of primary melanoma by microarray data analysis

12 citations , September 2022 in “Frontiers in Genetics”

This study identified seven genes that may serve as biomarkers for diagnosing skin cutaneous melanoma by analyzing the relationship between UV exposure, ferroptosis, and the cancer's pathology.

research 644 Tumor cell adhesion as a risk factor for SLN metastasis and predictor of disease recurrence in primary cutaneous melanoma

April 2016 in “Journal of Investigative Dermatology”

This study found that adding cell adhesion-linked gene expression variables improved the identification of patients with SLN metastases within 90 days of melanoma diagnosis compared to using clinicopathologic variables alone.

research 15^thJornada de DermatologÃa of the Faculty of Medicine, ClÃnica Alemana â University of Desarrollo, Santiago, Chile, October 22-24, 2009

November 2009 in “International Journal of Dermatology”

No abstract is available for this article, and it presents no new clinical results.

research New developments in occupational dermatology

20 citations , September 2016 in “Journal der Deutschen Dermatologischen Gesellschaft”

This review discusses the addition of skin cancer caused by UV irradiation to the list of occupational diseases in Germany and reports no new clinical results.

View more "new primary melanomas" in research →

Community Join

5 / 1000+ results

community Male pattern baldness is not cosmetic.

224 upvotes 10 months ago

Male pattern baldness is linked to health risks and should be treated medically. Finasteride is effective and should be insurance-covered.

community Why the cure is not yet found and why it is always 5 years away? Why no hopes on PP405, GT, KX, Hair cloning, AMP, etc, etc, etc

19 upvotes 1 year ago

Skepticism about hair loss research motivations, suggesting financial interests hinder finding a cure. Mentions treatments like minoxidil, finasteride, and dutasteride, but notes they are not cures.

community Checking in: is fin and min still the latest science

9 upvotes 2 weeks ago

Finasteride and minoxidil remain the primary treatments for hair loss, with dutasteride being a more potent alternative. New treatments like VDPHL01 and topical antiandrogens are in development.

community New Light Therapy Can Suppress a Key Marker of Hair Loss by 92%

in Research/Science 201 upvotes 5 months ago

A new light therapy claims to reduce hair loss markers by 92% using a specific wavelength range. Users discuss the cost and effectiveness of devices, with some expressing skepticism and others considering alternative treatments like red light therapy and vitamin D exposure.

community What new hair-loss treatments actually look exciting right now (Oct 2025)

171 upvotes 11 months ago

New hair loss treatments include Breezula, PP405, ET-02, KX-826, GT20029, VDPHL01, and CosmeRNA, with some showing promise in reactivating stem cells and reversing greying. Breezula and VDPHL01 are highlighted as potential add-ons or alternatives to current treatments like finasteride and minoxidil.

View more "new primary melanomas" in community →

Learn

2 / 800 results

learn Scalp Micropigmentation

What is Scalp Micropigmentation and how does it help people with visible hair loss? Scalp Micropigmentation creates the illusion of hair follicles on the scalp for visible hair loss.

learn KX-826

Kintor Pharmaceutical: KX-826, a New Name in Hair Loss Research KX-826 (pyrilutamide) is an experimental topical androgen receptor blocker from Kintor Pharmaceutical and is not approved as a medicine anywhere. Its first China Phase III trial did not beat placebo; the company reported in March 2026 that a later Phase III of a 1.0% formulation met its primary endpoint, but these results are company announcements, not peer-reviewed, and long-term safety is unknown.

View more "new primary melanomas" in learn →

Clinics

6 / 22 results

All 22 clinic results →

Experts

— no results

Try a deeper search in experts →